To include your compound in the COVID-19 Resource Center, submit it here.

Novo Nordisk, Sun Pharmaceutical endocrine news

The U.S. sales of Prandin and PrandiMet amounted to about DKK1 billion ($178.9 million) in 2010. PrandiMet is a combination of repaglinide, a short-acting beta-cell stimulating

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE